Table 2 Standardised incidence ratios and absolute excess risks for subsequent primary gliomas by childhood cancer diagnosis.
All glioma | Glioma grade I–II | Glioma grade III–IV | |||||||
|---|---|---|---|---|---|---|---|---|---|
Childhood cancer type | Obs | SIR (95% CI) | AER (95% CI) | Obs | SIR (95% CI) | AER (95% CI) | Obs | SIR (95% CI) | AER (95% CI) |
Overall | 279 | 7.5 (6.7,8.5) | 1.9 (1.7,2.2) | 136 | 6.0 (5.1,7.1) | 0.9 (0.7,1.1) | 143 | 12.0 (10.2,14.2) | 1.0 (0.9,1.2) |
CNS tumour | 132 | 16.2 (13.7,19.2) | 4.7 (3.9,5.6) | 72 | 14.4 (11.4,18.2) | 2.5 (2.0,3.3) | 60 | 22.4 (17.4,28.8) | 2.2 (1.7,2.8) |
Leukaemia | 68 | 11.2 (8.8,14.2) | 2.4 (1.8,3.1) | 23 | 6.5 (4.3,9.8) | 0.8 (0.5,1.2) | 45 | 25.2 (18.8,33.7) | 1.7 (1.2,2.3) |
Soft tissue sarcoma | 18 | 6.1 (3.9,9.7) | 1.6 (0.9,2.8) | 9 | 5.1 (2.7,9.8) | 0.8 (0.3,1.8) | 9 | 9.1 (4.7,17.5) | 0.9 (0.4,1.8) |
Non-Hodgkin lymphoma | 10 | 4.6 (2.5,8.5) | 1.1 (0.5,2.5) | 4 | 3.2 (1.2,8.6) | 0.4 (0.1,1.6) | 6 | 7.6 (3.4,17.0) | 0.7 (0.3,1.9) |
Retinoblastoma | 9 | 4.5 (2.3,8.6) | 1.0 (0.4,2.3) | 4 | 3.4 (1.3,9.0) | 0.4 (0.1,1.6) | 5 | 7.1 (3.0,17.1) | 0.6 (0.2,1.7) |
Neuroblastoma | 6 | 4.0 (1.8,9.0) | 0.7 (0.3,2.1) | 4 | 4.6 (1.7,12.2) | 0.5 (0.1,1.8) | 2 | 4.5 (1.1,18.2) | 0.3 (0.0,1.5) |
Bone Sarcoma | 7 | 3.5 (1.7,7.4) | 0.9 (0.3,2.4) | 6 | 5.0 (2.3,11.2) | 0.8 (0.3,2.3) | 1 | 1.4 (0.2,1.0) | 0.1 (0.0,41.6) |
Hodgkin lymphoma | 10 | 3.0 (1.6,5.6) | 0.7 (0.3,1.7) | 6 | 3.0 (1.4,6.8) | 0.4 (0.1,1.3) | 4 | 3.4 (1.3,9.1) | 0.3 (0.1,1.1) |
Wilms tumour | 7 | 2.6 (1.2,5.4) | 0.4 (0.1,1.3) | 4 | 2.5 (0.9,6.6) | 0.2 (0.0,1.1) | 3 | 3.5 (1.1,10.7) | 0.2 (0.0,1.0) |
Other | 12 | 1.9 (1.1,3.4) | 0.3 (0.1,1.0) | 4 | 1.0 (0.4,2.6) | – | 8 | 4.6 (2.3,9.1) | 0.3 (0.1,0.8) |
